Rahime Aydın KAYALI
(Sağlık Bilimleri Üniversitesi, Dr. Suat Seren Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Yoğun Bakım Anabilim Dalı , İzmir, Türkiye)
Serir Aktoğu ÖZKAN
(Sağlık Bilimleri Üniversitesi, Dr. Suat Seren Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı , İzmir, Türkiye)
(Sağlık Bilimleri Üniversitesi, Dr. Suat Seren Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitimi ve Araştırma Hastanesi, Tıbbi Mikrobiyoloji Laboratuvarı, İzmir, Türkiye)
Onur Fevzi ERER
(Sağlık Bilimleri Üniversitesi, Dr. Suat Seren Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı , İzmir, Türkiye)
Yıl: 2021Cilt: 22Sayı: 1ISSN: 2149-2530Sayfa Aralığı: 45 - 49İngilizce

24 0
The Relation Between the Emergence of Fluoroquinolone Resistance and Fluoroquinolone Exposure in New Cases of Active Pulmonary Tuberculosis
OBJECTIVE: This study aimed to determine the ratio of fluoroquinolone (FQ) exposure before the diagnosis of patients with a new case of active pulmonary tuberculosis (TB) and to investigate the correlation of this treatment with the emergence of FQ-resistant strains.MATERIAL AND METHODS: In this retrospective comparative case series study, a total of 132 patients, who had been diagnosed with adult, culture-positive, active pulmonary TB were reviewed. The FQ group had 30 patients who had had ≥1 time and ≥7 days of FQ exposure within 1 year before the diagnoses. The control group included an equal number of patients with TB with similar demographic characteristics (non-FQ group). Ofloxacin (OFX) and moxifloxacin (MFX) resistance were examined at 2 different concentrations (2 and 4 mg/L for OFX; 0.25 and 0.5 mg/L for MFX).RESULTS: Of the 132 patients, 30 (22%) had 7 days or longer of FQ monotherapy within 1 year of initiation of anti-TB treatment. FQ resistance was detected in 2 (3.3%) patients. In the FQ group, MFX resistance at 0.25 mg/L concentration was observed in 1 patient, whereas another patient had OFX and MFX resistance at 4 mg/L and 0.5 mg/L concentrations, respectively. In the non-FQ group, no FQ resistance was detected in any of the patients. No statistically significant difference in terms of development of FQ resistance was found between the ratios of FQ and non-FQ groups (p=0.492). Although there was no statistically significant difference, 2 patients, in whom resistance was detected, had FQ exposure before their diagnosis.CONCLUSION: The FQ exposure ratio before the diagnosis is high (22%) in this cohort that includes patients with new active pulmonary TB, and the presence of patients with FQ resistance (even if only a few) should be a noteworthy and cautionary result in terms of FQ exposure and resistance development.
DergiAraştırma MakalesiErişime Açık
  • 1. Chang KC, Nuermberger E, Sotgiu G, et al. New drugs and regimens for tuberculosis. Respirology 2018;23:978-90. [Crossref]
  • 2. World Health Organization. (2019). Global tuberculosis report 2019. Geneva; 2019. Report No. WHO/CDS/TB/2019.15 Licence: CC BY-NC-SA 3.0 IGO.
  • 3. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis ISBN:978 92 4 154880 9. WHO reference number: WHO/HTM/TB/2014.11
  • 4. Kabbani S, Hersh AL, Shapiro DJ, et al. Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits. Clin Infect Dis 2018; 67:134-6. [Crossref]
  • 5. Chen TC, Lu P-L, Lin C-Y, et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: A systematic review and meta-analysis. Int J Infect Dis 2011;15:e211-6. [Crossref]
  • 6. Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61:903-8. [Crossref]
  • 7. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J 2012;39:807-19. [Crossref]
  • 8. Pai M, Yadav P, Anupindi R. Tuberculosis control needs a complete and patient-centric solution. Lancet Glob Health 2014;2:e189-90. [Crossref]
  • 9. Migliori GB, Langendam MW, D’Ambrosio L, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012;40:814-22. [Crossref]
  • 10. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014;44:1412-7. [Crossref]
  • 11. Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003;349:1977-8. [Crossref]
  • 12. Wang J-Y, Lee C-H, Yu M-C, et al. Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study. Eur Respir J 2015;46:567-70. [Crossref]
  • 13. Clinical and Laboratory Standards Institute (CLSI). Susceptibility Testing of Mycobacteria,Nocardia, and Other Aerobic Actinomycetes; Approved Standard- Second Edition. CLSI document M24 -A2. Pennsylvania, 2011.
  • 14. Soylar ÖK, Kılınç O, Ellidokuz H. Comparison of Patients with Community-Acquired Pneumonia Who Did and Did not Receive Treatment in Accordance with the 2009 Pneumonia Guideline of Turkish Thoracic Society. Turk Thorac J 2015;16:64-7. [Crossref]
  • 15. Park IN, Hong SB, Oh YM, et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007;11:319-24.
  • 16. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-42. [Crossref]
  • 17. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003;37:1448-52. [Crossref]
  • 18. Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009;48:1354-60. [Crossref]
  • 19. Yılmaz FF, Eraç B, Ermertcan Ş, et al. In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates. Tuberk Toraks 2018;66:32-6. [Crossref]
  • 20. Ginsburg AS, Sun R, Calamita H, et al. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob Agents Chemother 2005;49:3977-9. [Crossref]
  • 21. Webster D, Long R, Shandro C, et al. Fluoroquinolone resistance in renal isolates of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2010;14:217-22.
  • 22. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180:365-70. [Crossref]
  • 23. Jeon CY, Calver AD, Victor TC, et al. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int J Tuberc Lung Dis 2011;15:77-83.
  • 24. van den Boogaard J, Semvua HH, van Ingen J, et al. Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania. J Antimicrob Chemother 2011;66: 1810-4. [Crossref]
  • 25. Ho J, Jelfs P, Sintchenko V. Fluoroquinolone resistance in nonmultidrug-resistant tuberculosis a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis 2014;26:149-53. [Crossref]
  • 26. Lee JY, Lee HJ, Kim YK, et al. Impact of fluoroquinolone exposure prior to tuberculosis diagnosis on clinical outcomes in immunocompromised patients. Antimicrob Agents Chemother 2016;60:4005-12. [Crossref]
  • 27. Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel) 2014;3:317-40. [Crossref]
  • 28. Chien JY, Yu CJ, Hsueh PR. High incidence of fluoroquinolone resistance and effect of efflux pump inhibitors on moxifloxacin resistance among Mycobacterium tuberculosis isolates causing urinary tract infection in Taiwan. Int J Antimicrob Agents 2017;50:491-5. [Crossref]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.